University Hospital of North Norway
- Address
- Postboks 100, 9038 Tromsø, Norway
Oncology & Cancer Therapeutics
The University Hospital of North Norway leads research in improving treatment effectiveness for aggressive cancers, especially in children and adults with high‑risk disease.
- Frontline chemotherapy comparisons for very high‑risk sarcoma
- Dose‑intense schedules using novel drug combinations
- Pre‑operative versus standard post‑operative radiotherapy strategies
- Extended maintenance chemotherapy regimens
The program aims to define optimal protocols for Rhabdomyosarcoma and other sarcoma subtypes while also supporting early‑stage breast cancer care.
Cardiac Safety in Oncology
Trials assess methods to protect heart function during cancer treatment, focusing on patients receiving anthracycline‑containing regimens.
- Monitoring left ventricular systolic function with advanced imaging
- Evaluating preventive use of heart‑protective medications
- Comparing pre‑treatment cardiac baselines to post‑therapy outcomes
One study examines whether sacubitril/valsartan can attenuate chemotherapy‑induced cardiac dysfunction.
Sarcoma Treatment Innovation
Research targets high‑risk sarcoma, testing new systemic therapy regimens and radiotherapy approaches to improve survival.
- Combination of irinotecan with ifosfamide, vincristine and actinomycin D
- Dose escalation of radiotherapy for patients with higher local failure risk
- Whole‑body radiotherapy versus primary‑site only treatment in metastatic disease
- Adding regorafenib to irinotecan‑based therapy for relapsed disease
The overarching study, FaR‑RMS, evaluates the new regimen IrIVA across frontline and relapsed settings.
Heart Failure and Oncology Integration
The department explores management of Heart Failure in patients undergoing cancer therapy, seeking coordinated cardiac and oncologic care.
- Identification of cardiac biomarkers predictive of treatment‑related decline
- Integration of cardiology consults into oncology treatment plans
- Evaluation of novel heart‑failure therapies alongside chemotherapy
Advanced imaging with cardiovascular magnetic resonance supports precise assessment of cardiac function during trials.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Oslo University Hospital HF1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital of North Norway
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Intravenous Thrombolysis with Tenecteplase in Acute Ischemic Stroke Patients on Factor Xa Inhibitors: A Comparative Study | Oslo University Hospital HF | Phase III | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alteplase | 1 | Unknown | 2025-03-10 | 2025-03-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.